Latest database descriptions

The main objective is to compare versus standard of care short-term mortality rates in advanced or metastatic cancer patients who are positive for COVID-19 treated with an autophagy inhibitor (GNS561), an anti-NKG2A (monalizumab) or an anti-C5aR (avdoralimab).
The primary endpoint will be the 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization.
The 28-day survival rate will be described in each arm of each cohort.

To assess the impact of the Covid-19 pandemic and subsequent lockdown on the number and clinical characteristics of patients with retinal detachment (RD) in a French public university eye hospital.

The primary objective is to describe the mortality of cancer patients under active anticancer treatment who underwent diagnostic procedures (positive or negative) for a suspicion of COVID-19.

The primary endpoint will be the mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative).

To report the incidence of Intensive Care Unit Cardiac Arrest (ICUCA) among patients hospitalized in French Intensive Care Unit (ICU) for COVID-19.
To report morbidity and mortality among COVID-19 patients admitted alive in ICU for an out-of-hospital cardiac arrest (OHCA) or an in-hospital cardiac arrest (IHCA).